Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$22.64
3.0715.69%
At close: Dec 15, 4:00 PM EST
$22.50
-0.14-0.62%
After Hours: 4:26 PM EST
Comments
Loading...
Immunome Analyst Ratings and Price Targets | NASDAQ:IMNM | Benzinga
Immunome Inc has a consensus price target of $23 based on the ratings of 13 analysts. The high is $36 issued by Truist Securities on December 1, 2025. The low is $8 issued by Cantor Fitzgerald on March 20, 2023. The 3 most-recent analyst ratings were released by Truist Securities, Stephens & Co., and Goldman Sachs on December 1, 2025, November 17, 2025, and September 22, 2025, respectively. With an average price target of $31.67 between Truist Securities, Stephens & Co., and Goldman Sachs, there's an implied 40.74% upside for Immunome Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Truist Securities
Stephens & Co.
Goldman Sachs
Craig-Hallum
Guggenheim
1calculated from analyst ratings
Analyst Ratings for Immunome
FAQ
What is the target price for Immunome (IMNM) stock?
The latest price target for Immunome (NASDAQ:IMNM) was reported by Truist Securities on December 1, 2025. The analyst firm set a price target for $36.00 expecting IMNM to rise to within 12 months (a possible 60.00% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Immunome (IMNM)?
The latest analyst rating for Immunome (NASDAQ:IMNM) was provided by Truist Securities, and Immunome initiated their buy rating.
When was the last upgrade for Immunome (IMNM)?
There is no last upgrade for Immunome
When was the last downgrade for Immunome (IMNM)?
There is no last downgrade for Immunome.
When is the next analyst rating going to be posted or updated for Immunome (IMNM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immunome, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immunome was filed on December 1, 2025 so you should expect the next rating to be made available sometime around December 1, 2026.
Is the Analyst Rating Immunome (IMNM) correct?
While ratings are subjective and will change, the latest Immunome (IMNM) rating was a initiated with a price target of $0.00 to $36.00. The current price Immunome (IMNM) is trading at is $22.50, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
